


MORE COVID DISTURBING EVIDENCE: FROM FDA (KAREN KINGSTON PROVIDED) FRIDAY, NOV 19, 2021:  
PFIZER IS LYING TO THE AMERICAN PUBLIC AND WANTS TO HIDE WHAT REALLY IS IN THE SHOTS



FDA AND PFIZER FILE FOR 55 YEAR DELAY IN PRESENTING THE CONTENTS OF PFIZER

IN SEPTEMBER 27 DOCUMENTS PFIZER ADMITTED 409 MAJOR INJURIES FROM INJECTED PEOPLE.

100 CHILDREN STUDY SHOWED CLEARLY THE INJECTIONS ARE HARMFUL TO CHILDREN

PFIZER DOES NOT WANT TO ADMIT THAT THEY ARE INJECTING PEOPLE WITH AN ADVANCED BIO  
TECHNOLOGY

## Symptomatic but "NOT CONFIRMED" COVID-19 within 7 DAYS After Dose 1 or 2, pg. 41

### Suspected COVID-19 Cases

Among 3,410 total cases of suspected but unconfirmed COVID-19 in the overall study population, 1,594 occurred in the vaccine group vs. 1816 in the placebo group. Suspected COVID-19 cases that occurred within 7 days after any vaccination were 409 in the vaccine group vs. 287 in the placebo group. It is possible that the imbalance in suspected COVID-19 cases occurring in the 7 days postvaccination represents vaccine reactogenicity with symptoms that overlap with those of COVID-19. Overall though, these data do not raise a concern that protocol-specified reporting of suspected, but unconfirmed COVID-19 cases could have masked clinically significant adverse events that would not have otherwise been detected.

<https://www.fda.gov/media/144416/download>

## PFIZER'S OWN ADMITTED ADVERSE REACTIONS TO THE INJECTIONS

For another secondary endpoint, the case definition for a severe COVID-19 case was a confirmed COVID-19 case with at least one of the following:

- Clinical signs at rest indicative of severe systemic illness (RR  $\geq 30$  breaths per minute, HR  $\geq 125$  beats per minute, SpO<sub>2</sub>  $\leq 93\%$  on room air at sea level, or PaO<sub>2</sub>/FiO<sub>2</sub>  $< 300$  mm Hg);
- Respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO);
- Evidence of shock (SBP  $< 90$  mm Hg, DBP  $< 60$  mm Hg, or requiring vasopressors)
- Significant acute renal, hepatic, or neurologic dysfunction;
- Admission to an ICU;
- Death.

14

<https://www.fda.gov/media/144416/download>

THESE ARE THE SIGNIFICANT ADVERSE EFFECTS THAT 409 PEOPLE TAKING THE PFIZER SHOT EXPERIENCED WITHIN 7 DAYS AFTER GETTING THE SHOTS. THE CONTRACT RESEARCH GROUPS GIVING

SHOTS IN OCT 22 2020 WERE SEEING MASSIVE ADVERSE EFFECTS AND ALERTED PFIZER THAT THEY HAD TO HAVE DETAILED INFORMATION ON WHAT ARE THE ACTUAL EXPECTED ADVERSE EFFECTS.

PFIZER'S LIST OF POTENTIAL AVERSE EFFECTS WITH THE INJECTIONS

**FDA/CBER Plans for Monitoring COVID-19 Vaccine Safety & Effectiveness**  
Presented by: Steve Anderson, PhD, MPP – Dir. Office of Biostats & Epidemiology, CBER  
October 22, 2020 – Vaccines & Related Biological Products Advisory Committee (VRBPAC) Meeting

**FDA Safety Surveillance of COVID-19 Vaccines :**  
**DRAFT Working list of possible adverse event outcomes**  
**\*\*\*Subject to change\*\*\***

▪ Guillain-Barré syndrome	▪ Deaths
▪ Acute disseminated encephalomyelitis	▪ Pregnancy and birth outcomes
▪ Transverse myelitis	▪ Other acute demyelinating diseases
▪ Encephalitis/myelitis/encephalomyelitis/ meningoencephalitis/meningitis/ encephalopathy	▪ Non-anaphylactic allergic reactions
▪ Convulsions/seizures	▪ Thrombocytopenia
▪ Stroke	▪ Disseminated intravascular coagulation
▪ Narcolepsy and cataplexy	▪ Venous thromboembolism
▪ Anaphylaxis	▪ Arthritis and arthralgia/joint pain
▪ Acute myocardial infarction	▪ Kawasaki disease
▪ Myocarditis/pericarditis	▪ Multisystem Inflammatory Syndrome in Children
▪ Autoimmune disease	▪ Vaccine enhanced disease

[https://www.fda.gov/media/143557/download?fbclid=IwAR1SooRjTDuhBPqM4TiD3O7YgrX4eAp3CCqB7SzCk04CMve\\_QzgtMNPfNkr](https://www.fda.gov/media/143557/download?fbclid=IwAR1SooRjTDuhBPqM4TiD3O7YgrX4eAp3CCqB7SzCk04CMve_QzgtMNPfNkr)

mifight

**FDA**  
Center for Biologics  
Evaluation and Research

THIS DATA WAS PUT OUT OCT 21 TO SUBCONTRACTORS GIVING THE SHOTS BECAUSE THEY WERE HAVING SO MUCH ADVERSE REACTIONS TO THE SHOTS.

FDA AND PFIZER USED THE “COVID BREAK THROUGH” CASE LABEL TO COVER UP THE ACTUAL PROBLEM OF SEVERE ADVERSE REACTIONS TO THE SHOTS.

IN JUNE THE FDA ANNOUNCED THAT NONE OF THESE SHOTS WERE AS EFFECTIVE AS CHILDREN'S OWN IMMUNE DEFENSE SYSTEM, IT IS IN ALL THE CHILDREN EVALUATION DOCUMENTS. THEY HAVE THESE SHOTS CAUSING IMMUNOBRIDGING, AND FAUCI CAME UP WITH THE SHOTS CAUSE YOUR SYSTEM TO GIVE AN AUTOIMMUNE RESPONSE TO INCREASE THE BODY'S DEFENSE MECHANISM, WHEN THE TRUTH IS THAT YOUR AUTOIMMUNE SYSTEM BEGINS ATTACKING YOUR BODY ORGANS FROM THE EFFECTS OF THESE SHOTS.

### 3. Chemistry, Manufacturing and Controls (CMC)

#### a. Product Quality

##### COMIRNATY Manufacturing Overview

The mRNA in COMIRNATY is a single-stranded, 5'-capped mRNA encoding the full-length SARS-CoV-2 spike glycoprotein derived from the Wuhan-Hu-1 isolate (GenBank MN908947.3 and GenBank QHD43416.1). The antigen-coding RNA sequence is codon-optimized and contains two proline mutations ((b) (4)), which ensures an antigenically optimal trimerized pre-fusion conformation (S-2P). The RNA also contains common structural elements, including 5'-cap, 5'-UTR, 3'-UTR, and poly(A) tail, all of which are designed for mediating high RNA stability and translation efficiency. During RNA transcription, (b) (4) is replaced with the (b) (4). This nucleoside substitution has been demonstrated to enhance translation of *in vitro* transcribed mRNA while reducing its reactogenicity.

<https://www.fda.gov/media/151733/download>

THE ABOVE SLIDE SHOWS THE PFIZER BIOWAPON THAT WAS AUTHORIZED BY FDA IN AUGUST AND SHOWS THE BIOWEAPON SPIKE PROTEING.

THE NEXT SLIDE SHOWS THE BIOWEAPON CAPABILITY OF THIS MRNA AND THAT NIH FUNDED THE RESEARCH, AND RETAINS CERTAIN RIGHTS OVER THE INVENTION

#### NIH SPONSORED AND HAS OWNERSHIP OF VACCINE NANOTECHNOLOGY FOR A BIOWEAPON

(12) **United States Patent**  
von Andrian et al.

(10) Patent No.: US 9,539,210 B2  
(45) Date of Patent: Jan. 10, 2017

(54) VACCINE NANOTECHNOLOGY

(58) Field of Classification Search

#### STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under Grant Nos. CA119349, AI069259, AI072252, EB003647, HL056949 and AI061663 awarded by the National Institutes of Health. The government has certain rights in the invention.

9

Y is polyalkylene glycol or polyalkylene oxide. In some embodiments, X is PLGA, PLA or PGA. In some embodiments, Z is absent.

In some aspects, a composition comprising a nanocarrier comprising an immunostimulatory agent is provided. In some embodiments, the composition further comprises an antigen and/or a targeting moiety. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a water soluble, non-adhesive polymer. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a biodegradable polymer. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a biocompatible polymer. In some embodiments, the biocompatible polymer is a conjugate of a water soluble, non-adhesive polymer conjugated to a biodegradable polymer. In some embodiments, the antigen is a B cell antigen. In some embodiments, the B cell antigen is not a T cell antigen. In some embodiments, the nanocarrier further comprises a T cell antigen. In some embodiments, the antigen is a T cell antigen.

In some aspects, a composition comprising a nanocarrier comprising a small molecule, an immunostimulatory agent, and a T cell antigen is provided.

In some embodiments, the small molecule is a toxin. In some embodiments, the toxin is from a chemical weapon, an agent of biowarfare, or a hazardous environmental agent.

<https://patentimages.storage.googleapis.com/29/d1/ca/18013ced0621f0/US9539210.pdf>

FRANCIS COLLINS IS SUING MODERNA FOR MONIES FROM LAUNCHING THIS BIOWEAPON, AND WANTING TO BENEFIT FROM THE MONIES.

**NIH SPONSORED AND HAS OWNERSHIP OF  
VACCINE NANOTECHNOLOGY FOR A BIOWEAPON**

(12) **United States Patent**  
von Andrian et al.

(10) **Patent No.:** **US 9,539,210 B2**

(45) **Date of Patent:** **Jan. 10, 2017**

(54) **VACCINE NANOTECHNOLOGY**

(58) **Field of Classification Search**

**STATEMENT OF GOVERNMENT SUPPORT**

This invention was made with government support under Grant Nos. CA119349, AI069259, AI072252, EB003647, HL056949 and AI061663 awarded by the National Institutes of Health. The government has certain rights in the invention.

9

Y is polyalkylene glycol or polyalkylene oxide. In some embodiments, X is PLGA, PLA or PGA. In some embodiments, Z is absent.

In some aspects, a composition comprising a nanocarrier comprising an immunostimulatory agent is provided. In some embodiments, the composition further comprises an antigen and/or a targeting moiety. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a water soluble, non-adhesive polymer. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a biodegradable polymer. In some embodiments, at least one of the antigen, targeting moiety, and immunostimulatory agent is conjugated to a biocompatible polymer. In some embodiments, the biocompatible polymer is a conjugate of a water soluble, non-adhesive polymer conjugated to a biodegradable polymer. In some embodiments, the antigen is a B cell antigen. In some embodiments, the B cell antigen is not a T cell antigen. In some embodiments, the nanocarrier further comprises a T cell antigen. In some embodiments, the antigen is a T cell antigen.

In some aspects, a composition comprising a nanocarrier comprising a small molecule, an immunostimulatory agent, and a T cell antigen is provided.

In some embodiments, the small molecule is a toxin. In some embodiments, the toxin is from a chemical weapon, an agent of biowarfare, or a hazardous environmental agent.

<https://patentimages.storage.googleapis.com/29/d1/ca/18013ced0621f0/U59539210.pdf>

35/36 / 54/20 ◀ ▶ ◻ ◻ ◻ ◻ ◻ rumble